LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives $35.40 Average PT from Brokerages

LENZ Therapeutics, Inc. (NASDAQ:LENZGet Free Report) has been given an average recommendation of “Buy” by the seven ratings firms that are covering the firm, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $35.40.

A number of equities research analysts recently commented on the company. Raymond James assumed coverage on LENZ Therapeutics in a report on Friday, September 27th. They set an “outperform” rating and a $37.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $38.00 price target on shares of LENZ Therapeutics in a research report on Thursday, November 7th. Finally, William Blair raised shares of LENZ Therapeutics to a “strong-buy” rating in a report on Friday, August 30th.

Check Out Our Latest Report on LENZ

Hedge Funds Weigh In On LENZ Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. purchased a new position in LENZ Therapeutics in the 1st quarter valued at about $4,621,000. Parkman Healthcare Partners LLC purchased a new position in shares of LENZ Therapeutics in the third quarter valued at approximately $3,308,000. Bank of New York Mellon Corp lifted its position in shares of LENZ Therapeutics by 255.4% in the second quarter. Bank of New York Mellon Corp now owns 39,737 shares of the company’s stock valued at $687,000 after acquiring an additional 28,556 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new stake in shares of LENZ Therapeutics in the third quarter worth approximately $743,000. Finally, Marshall Wace LLP purchased a new stake in shares of LENZ Therapeutics during the second quarter worth approximately $390,000. 54.32% of the stock is currently owned by institutional investors and hedge funds.

LENZ Therapeutics Trading Up 5.1 %

NASDAQ:LENZ opened at $32.41 on Friday. LENZ Therapeutics has a 12 month low of $14.42 and a 12 month high of $38.93. The firm has a fifty day simple moving average of $31.37 and a 200-day simple moving average of $24.80.

LENZ Therapeutics (NASDAQ:LENZGet Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.09. During the same period last year, the firm posted ($1.33) EPS. On average, sell-side analysts predict that LENZ Therapeutics will post -2.09 earnings per share for the current year.

LENZ Therapeutics Company Profile

(Get Free Report

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Recommended Stories

Analyst Recommendations for LENZ Therapeutics (NASDAQ:LENZ)

Receive News & Ratings for LENZ Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENZ Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.